ARTICLE | Company News
XenoPort gains on restructuring plans
October 2, 2015 11:57 PM UTC
XenoPort Inc. (NASDAQ:XNPT) gained $0.84 (24%) to $4.32 after the company said it is replacing its CEO and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil.
EVP and COO Vincent Angotti succeeds Ronald Barrett, who retired as CEO and director. Angotti has led Horizant's commercialization. The company will also cut about 25 jobs, including positions related to the XP23829 program. ...